Back to top

SCYNEXIS: Buy Rating Affirmed Amid Strategic Advancements and Promising Antifungal Innovations

Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS (SCYX – Research Report) yesterday and set a price target of $4.00. Jason Mc...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

SCYNEXIS, Inc. (SCYX)